Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aß42/40 ratio to identify presence of brain amyloid.
Alzheimers Dement
; 20(5): 3179-3192, 2024 05.
Article
in En
| MEDLINE
| ID: mdl-38491912
ABSTRACT
BACKGROUND:
With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment.METHODS:
High-throughput, mass spectrometry-based assays were used to measure %p-tau217 and amyloid beta (Aß)42/40 ratio in blood samples from 583 individuals with suspected AD (53% positron emission tomography [PET] positive by Centiloid > 25). An algorithm (PrecivityAD2 test) was developed using these plasma biomarkers to identify brain amyloidosis by PET.RESULTS:
The area under the receiver operating characteristic curve (AUC-ROC) for %p-tau217 (0.94) was statistically significantly higher than that for p-tau217 concentration (0.91). The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2, was 0.94, yielding 88% agreement with amyloid PET. Diagnostic performance of the APS2 was similar by ethnicity, sex, age, and apoE4 status.DISCUSSION:
The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Peptide Fragments
/
Mass Spectrometry
/
Algorithms
/
Brain
/
Biomarkers
/
Amyloid beta-Peptides
/
Tau Proteins
/
Positron-Emission Tomography
/
Alzheimer Disease
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Alzheimer's & dementia
/
Alzheimers Dement
/
Alzheimers dememt
Year:
2024
Type:
Article
Affiliation country:
United States